ONECYTE BIOTECHNOLOGIES, INC.
[email protected]
SBIR Phase I: A high throughput microfluidic platform to accelerate biomanufacturing transitions in the COVID-19 response
SBIR Phase II: A high throughput microfluidic platform to accelerate biomanufacturing transitions in biologics development